Metraipolis › archive › dc_b5ee953b22df

Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC — Europe PMC PMID:40860822

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40860822
DOI
10.3389/fonc.2025.1544967
License (as archived)
solo-consultazione
Archived
2026-11-10T17:49:00.646Z
SHA-256 of the archived text
6bbc08c9d991244dd8f8abae7f1b204a30d01bc6c509a39d7bbcf9c4cdcd0b66
Stable URL of this page
https://metraipolis.com/documento/dc_b5ee953b22df

How to cite

Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC — Europe PMC PMID:40860822 — Europe PMC (en), https://europepmc.org/article/MED/40860822 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b5ee953b22df (Metraipolis archive dc_b5ee953b22df, sha256 6bbc08c9d991244dd8f8abae7f1b204a30d01bc6c509a39d7bbcf9c4cdcd0b66)
BibTeX
@misc{dcb5ee953b22df,
  title = {Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC — Europe PMC PMID:40860822},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40860822},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b5ee953b22df; sha256 6bbc08c9d991244dd8f8abae7f1b204a30d01bc6c509a39d7bbcf9c4cdcd0b66},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40860822. Agents can read the archived copy with the MCP tool read_document.